PolyPid Past Earnings Performance
Past criteria checks 0/6
PolyPid's earnings have been declining at an average annual rate of -9.7%, while the Pharmaceuticals industry saw earnings growing at 1% annually.
Key information
-9.7%
Earnings growth rate
61.1%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
PolyPid set to cut 20% jobs
Oct 20PolyPid's surgical site infections treatment eligible for marketing nod submission in EU
Sep 28PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections
Sep 02PolyPid GAAP EPS of -$1.23 misses by $0.60
Aug 10PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe
Aug 03PolyPid: Strong Pipeline, Close Catalysts
Apr 19Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?
Mar 18Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Nov 08We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth
Jul 15Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Mar 09PolyPid's oncoplex cancer program shows encouraging action in animal study
Dec 22PolyPid launches second late-stage trial with D-PLEX100 in surgical infections
Dec 16PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections
Nov 24Revenue & Expenses BreakdownBeta
How PolyPid makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -24 | 7 | 16 |
30 Sep 23 | 0 | -24 | 7 | 16 |
30 Jun 23 | 0 | -28 | 8 | 19 |
31 Mar 23 | 0 | -34 | 10 | 23 |
31 Dec 22 | 0 | -40 | 11 | 28 |
30 Sep 22 | 0 | -46 | 13 | 33 |
30 Jun 22 | 0 | -47 | 13 | 34 |
31 Mar 22 | 0 | -46 | 13 | 33 |
31 Dec 21 | 0 | -43 | 13 | 31 |
30 Sep 21 | 0 | -41 | 11 | 26 |
30 Jun 21 | 0 | -37 | 11 | 23 |
31 Mar 21 | 0 | -46 | 11 | 20 |
31 Dec 20 | 0 | -43 | 9 | 17 |
30 Sep 20 | 0 | -42 | 8 | 15 |
30 Jun 20 | 0 | -37 | 6 | 15 |
31 Mar 20 | 0 | -19 | 5 | 14 |
31 Dec 19 | 0 | -13 | 4 | 14 |
31 Dec 18 | 0 | 0 | 6 | 13 |
31 Dec 17 | 0 | -59 | 4 | 10 |
30 Sep 17 | 0 | -20 | 3 | 9 |
31 Dec 16 | 0 | -14 | 3 | 8 |
31 Dec 15 | 0 | -11 | 3 | 6 |
30 Jun 14 | 0 | -6 | 1 | 2 |
31 Mar 14 | 0 | -5 | 1 | 3 |
Quality Earnings: PYPD is currently unprofitable.
Growing Profit Margin: PYPD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PYPD is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare PYPD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PYPD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: PYPD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.